Amber O Molnar1, Chirag R Parikh2, Steven G Coca3, Heather Thiessen-Philbrook4, Jay L Koyner5, Michael G Shlipak6, Mary Lee Myers7, Amit X Garg8. 1. Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. 2. Section of Nephrology, Yale University School of Medicine, Veterans Affairs CT Healthcare System, and the Program of Applied Translational Research, New Haven, Connecticut; Department of Medicine, Veterans Affairs Medical Center, West Haven, Connecticut. Electronic address: chirag.parikh@yale.edu. 3. Section of Nephrology, Yale University School of Medicine, Veterans Affairs CT Healthcare System, and the Program of Applied Translational Research, New Haven, Connecticut. 4. Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada. 5. Section of Nephrology, Department of Medicine, University of Chicago, Pritzker School of Medicine, Chicago, Illinois. 6. Division of General Internal Medicine, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, California. 7. Division of Cardiac Surgery, Western University, London, Ontario, Canada. 8. Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Acute kidney injury (AKI) is a serious complication of cardiac operations for which there remains no specific therapy. Animal data and several observational studies suggest that statins prevent AKI, but the results are not conclusive, and many studies are retrospective in nature. METHODS: We conducted a multicenter prospective cohort study of 625 adult patients undergoing elective cardiac operations. All patients were taking statins and were grouped according to whether statins were continued or held in the 24 hours before operation. The primary outcome was AKI as defined by a doubling of serum creatinine or dialysis. The secondary outcome was the peak level of several kidney injury biomarkers. The results were adjusted for demographic and clinical factors. RESULTS: Continuing (vs holding) a statin before operation was not associated with a lower risk of AKI, as defined by a doubling of serum creatinine or dialysis (adjusted relative risk [RR] 1.09; 95% confidence interval [CI] 0.44, 2.70). However, continuing a statin was associated with a lower risk of elevation of the following AKI biomarkers: urine interleukin-18, urine neutrophil gelatinase-associated lipocalin, urine kidney injury molecule-1, and plasma neutrophil gelatinase-associated lipocalin (adjusted RR 0.34; 95% CI 0.18, 0.62), (adjusted RR 0.41; 95% CI 0.22, 0.76), (adjusted RR 0.37; 95% CI 0.20, 0.76), (adjusted RR 0.62; 95% CI 0.39, 0.98), respectively. CONCLUSIONS: Statins may prevent kidney injury after cardiac operations, as evidenced by lower levels of kidney injury biomarkers.
BACKGROUND:Acute kidney injury (AKI) is a serious complication of cardiac operations for which there remains no specific therapy. Animal data and several observational studies suggest that statins prevent AKI, but the results are not conclusive, and many studies are retrospective in nature. METHODS: We conducted a multicenter prospective cohort study of 625 adult patients undergoing elective cardiac operations. All patients were taking statins and were grouped according to whether statins were continued or held in the 24 hours before operation. The primary outcome was AKI as defined by a doubling of serum creatinine or dialysis. The secondary outcome was the peak level of several kidney injury biomarkers. The results were adjusted for demographic and clinical factors. RESULTS: Continuing (vs holding) a statin before operation was not associated with a lower risk of AKI, as defined by a doubling of serum creatinine or dialysis (adjusted relative risk [RR] 1.09; 95% confidence interval [CI] 0.44, 2.70). However, continuing a statin was associated with a lower risk of elevation of the following AKI biomarkers: urine interleukin-18, urine neutrophil gelatinase-associated lipocalin, urine kidney injury molecule-1, and plasma neutrophil gelatinase-associated lipocalin (adjusted RR 0.34; 95% CI 0.18, 0.62), (adjusted RR 0.41; 95% CI 0.22, 0.76), (adjusted RR 0.37; 95% CI 0.20, 0.76), (adjusted RR 0.62; 95% CI 0.39, 0.98), respectively. CONCLUSIONS: Statins may prevent kidney injury after cardiac operations, as evidenced by lower levels of kidney injury biomarkers.
Authors: Amber O Molnar; Steven G Coca; Phillip J Devereaux; Arsh K Jain; Abhijat Kitchlu; Jin Luo; Chirag R Parikh; J Michael Paterson; Nausheen Siddiqui; Ron Wald; Michael Walsh; Amit X Garg Journal: J Am Soc Nephrol Date: 2011-04-14 Impact factor: 10.121
Authors: Thomas L Nickolas; Kai M Schmidt-Ott; Pietro Canetta; Catherine Forster; Eugenia Singer; Meghan Sise; Antje Elger; Omar Maarouf; David Antonio Sola-Del Valle; Matthew O'Rourke; Evan Sherman; Peter Lee; Abdallah Geara; Philip Imus; Achuta Guddati; Allison Polland; Wasiq Rahman; Saban Elitok; Nasir Malik; James Giglio; Suzanne El-Sayegh; Prasad Devarajan; Sudarshan Hebbar; Subodh J Saggi; Barry Hahn; Ralph Kettritz; Friedrich C Luft; Jonathan Barasch Journal: J Am Coll Cardiol Date: 2012-01-17 Impact factor: 24.094
Authors: Salim S Virani; Vijay Nambi; Venkateshwar R Polsani; Vei-Vei Lee; MacArthur Elayda; Shun Kohsaka; Wei Pan; Ross M Reul; James M Wilson; Laura A Petersen; James T Willerson; Christie M Ballantyne Journal: Cardiovasc Ther Date: 2010-04 Impact factor: 3.023
Authors: Frank C Grenier; Salman Ali; Hina Syed; Ryan Workman; Frans Martens; Ming Liao; Y Wang; Pui-Yuen Wong Journal: Clin Biochem Date: 2009-12-21 Impact factor: 3.281
Authors: Azrina Md Ralib; John W Pickering; Geoffrey M Shaw; Prasad Devarajan; Charles L Edelstein; Joseph V Bonventre; Zoltan H Endre Journal: J Am Soc Nephrol Date: 2011-11-17 Impact factor: 10.121
Authors: Chirag R Parikh; Dennis G Moledina; Steven G Coca; Heather R Thiessen-Philbrook; Amit X Garg Journal: Kidney Int Date: 2016-04-23 Impact factor: 10.612
Authors: Frederic T Billings; Patricia A Hendricks; Jonathan S Schildcrout; Yaping Shi; Michael R Petracek; John G Byrne; Nancy J Brown Journal: JAMA Date: 2016-03-01 Impact factor: 56.272
Authors: Steven G Coca; Azadeh Zabetian; Bart S Ferket; Jing Zhou; Jeffrey M Testani; Amit X Garg; Chirag R Parikh Journal: J Am Soc Nephrol Date: 2015-12-28 Impact factor: 10.121